Browsing by Author "Cedres Perez, Susana"
Now showing items 1-9 of 9
-
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer
Yamamoto, Nobuyuki; Morán, Teresa; Gregorc, Vanesa; Dowell, Jonathan; Cedres Perez, Susana; Planchard, David; Hayashi, Hidetoshi (Springer, 2020-10) -
Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
Cedres Perez, Susana; Assaf, Juan David; Iranzo Gómez, Patricia; Callejo Perez, Ana; Pardo Aranda, Nuria; Navarro Mendivil, Alejandro; Martínez Marti, Alexandre; Marmolejo Castañeda, David; Rezqallah Aron, Maria Alejandra; Amat, Ramon; Pedrola Gómez, Anna; Felip Font, Enriqueta; Carbonell, Caterina; Frigola Rissech, Joan; Dienstmann, Rodrigo (Nature Research, 2021-11-01) -
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
Iranzo Gómez, Patricia; Pardo Aranda, Nuria; Callejo Perez, Ana; Cedres Perez, Susana; Martínez Marti, Alexandre; Navarro Mendivil, Alejandro; Soleda, Mireia; Jiménez Flores, José Antonio; Hernandez Losa, Javier; Vivancos Prellezo, Ana; Felip Font, Enriqueta; Amat, Ramon; Carbonell, Caterina; Frigola Rissech, Joan (BMJ, 2022-04) -
Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
Callejo Perez, Ana; Iranzo Gómez, Patricia; Diaz-Mejia, Nely; Marmolejo Castañeda, David; Assaf, Juan David; Cedres Perez, Susana; Martínez Marti, Alexandre; Navarro Mendivil, Alejandro; Pardo Aranda, Nuria; Amat, Ramon; Felip Font, Enriqueta; Carbonell, Caterina; Frigola Rissech, Joan (MDPI, 2021-07) -
Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient
Domingues, I.; Cedres Perez, Susana; Callejo Perez, Ana; Vivancos Prellezo, Ana; Martínez Marti, Alexandre; Felip Font, Enriqueta (Elsevier, 2020-01) -
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer
Navarro Mendivil, Alejandro; Callejo Perez, Ana; Iranzo Gómez, Patricia; Cedres Perez, Susana; Martínez Marti, Alexandre; Pardo Aranda, Nuria; Jiménez Flores, José Antonio; Sansano Valero, Irene; Mancuso, Francesco Mattia; Nuciforo, Paolo Giovanni; Vivancos Prellezo, Ana; Felip Font, Enriqueta; Amat, Ramon; Saoudi Gonzalez, Nadia; Carbonell, Caterina; Frigola Rissech, Joan (Wiley, 2021-04) -
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Haakensen, Vilde Drageset; Nowak, Anna K.; Ellingsen, Espen Basmo; Farooqi, Saima Jamil; Bjaanæs, Maria Moksnes; Horndalsveen, Henrik; Cedres Perez, Susana (BMC, 2021-05-31) -
Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
Iranzo Gómez, Patricia; Callejo Perez, Ana; Assaf Pastrana, Juan David; Molina, Gaspar; Lopez, Daniel Esteban; García Illescas, David; Pardo Aranda, Nuria; Navarro Mendivil, Alejandro; Martínez Marti, Alexandre; Cedres Perez, Susana; Amat, Ramon; Felip Font, Enriqueta; Carbonell, Caterina; Frigola Rissech, Joan (Frontiers Media, 2022-05-30) -
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)
Bosch-Barrera, J; Cedres Perez, Susana; Coves, J.; Garcia‑Campelo, Rosario; Guirado Risueño, María; Nadal, Ernest (Springer, 2021-05)